Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.

British journal of haematology - 1 Jun 2026

Goel Utkarsh, Dragomirescu Catalin, Zanwar Saurabh, Cassano Rafaella Cassano, Cicero Kara I, Cowan Andrew J, Banerjee Rahul, Anwer Faiz, Khouri Jack, Dima Danai

Abstract excerpt

Functional high-risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12-24 months of front-line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front-line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less effective front-line therapy. In this study, we combined data from three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to Multiple Myeloma

Share to Phenotype

Share to Prognosis

Share to Transplantation, Autologous

Source

Open in PubMed Open full text

Identifiers

PMID: 42023513
DOI: 10.1111/bjh.70490
PMCID: PMC13267472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.PMID 42023513Read ↗

Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profilingSemantic proximity Read ↗

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitionsSemantic proximity Read ↗

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaSemantic proximity Read ↗

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained responseSemantic proximity Read ↗

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.Semantic proximity Read ↗

Genomic characterization of functional high-risk multiple myeloma patients.Semantic proximity Read ↗

Current Review on High-Risk Multiple Myeloma.Semantic proximity Read ↗

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodySemantic proximity Read ↗

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseSemantic proximity Read ↗

Ultra high-risk myeloma.Semantic proximity Read ↗

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.Semantic proximity Read ↗

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.